Paw BLOCH | Cited by 545 | of Novo Nordisk, Copenhagen | Read 1 publication | Contact Paw BLOCH

2015年9月24日 · Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation.

Protracted GLP-1 compounds and therapeutic uses thereof.

2023年7月6日 · Article pubs.acs.org/jmc discovery of the once-weekly glucagon-like peptide‑1 (glp-1) analogue semaglutide jesper lau,* paw bloch, lauge schäffer, ingrid ...

2015年9月11日 · Semantic Scholar profile for Paw Bloch, with 31 highly influential citations and 4 scientific research papers.

2015年8月26日 · Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation.

2015年8月26日 · Liraglutide is an acylated Glucagon-Like Peptide-1 (GLP-1) analog that binds to serum albumin in vivo, and is approved for once daily treatment of diabetes as well as obesity. The aim of the...

ABSTRACT: Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation.

2007年12月28日 · [Translated] The present invention relates to a semi-recombinant method for the production of GLP-1 analogs and derivatives containing non-proteinogenic amino acids in the N-terminal portion using a combination of recombinant expression techniques and chemical peptide synthesis. NOVO NORDISK AS. China.